Sun Pharmaceutical Industries Ltd announced on July 14 that it has reached a settlement and license agreement with Incyte Corporation in connection with litigation over the drug LEQSELVI™ (deuruxolitinib) in the United States.
According to the company’s filing, Sun and Incyte have agreed to dismiss the ongoing litigation in the U.S. District Court for the District of New Jersey. Both companies will also mutually release all claims raised or that could have been raised in the lawsuit.
As part of the settlement, Incyte has granted Sun Pharma a limited, non-exclusive license to certain U.S. patents, including U.S. Patent No. 9,662,335, for the use of oral deuruxolitinib in specific non-hematology-oncology indications in the U.S., such as alopecia areata.
Sun Pharma will make an upfront payment to Incyte, along with ongoing royalty payments until the expiry of the licensed patents. The specific financial details of the agreement remain confidential.
“This settlement marks another step in our commitment to bring innovative therapies to patients while respecting intellectual property rights,” Sun Pharma said in its statement.
Sun Pharma is one of the world’s leading specialty generics companies, with a significant presence in India, the U.S., and over 100 countries globally. Its specialty portfolio includes products in dermatology, ophthalmology, and onco-dermatology.
The company emphasized that its vertically integrated operations and multicultural workforce enable it to deliver high-quality medicines worldwide.
For further details, stakeholders are encouraged to visit Sun Pharma’s website or contact the investor and media relations team as per the details in the release.
